|Day Low/High||22.25 / 22.43|
|52 Wk Low/High||19.52 / 27.00|
Merck (MKGAY) shares are falling but could rebound after European officials approved its $17 billion acquisition of Sigma-Aldrich.
U.S. stock futures fall as data shows Japan slips back into a recession; Actavis nears a deal to acquire Allergan, reports say; Halliburton and Baker Hughes reach merger deal.
European stocks backpedal on Monday, following Asia lower as Japan's economy unexpectedly fell into a recession.
European stocks rise Thursday, as positive news from companies including Merck KGaA and Alstom led benchmark indices back into positive territory.
European stock markets are mixed as a drop in German business confidence stokes new concerns about the pace of economic recovery in Europe.
German drug company Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich for $17 billion.
China's Ministry of Commerce imposes conditions on the $3.1 billion deal.
The much-anticipated lung cancer study shows ImClone's drug increases survival in lung cancer patients, but the results just meet statistical significance.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.